Dominika Maziec

Dominika Maziec

Auto-generated profile, based on publicly available information

Dominika Maziec

Department of Biomedical Informatics, Harvard Medical School, Boston, MA 02115, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2023 in Nature Methods
Verified
Journal Article
Closed access
PDF file
SLSehi L’yI
Sehi L’yI
DMDominika Maziec
Dominika Maziec
VSVictoria Stevens
Victoria Stevens
TMTrevor Manz
Trevor Manz
AVAlexander Veit
Alexander Veit
NGNils Gehlenborg
Nils Gehlenborg

14 October 2025 in bioRxiv
Verified
Preprint
Open access
YHYoo-Jin Jiny Ha
Yoo-Jin Jiny Ha
DMDominika Maziec
Dominika Maziec
JMJulia Markowski
Julia Markowski
SGStephanie J. Georges
Stephanie J. Georges
NPNancy L. Parmalee
Nancy L. Parmalee
PPPeter Park
Peter Park
Mosaic mutations in normal tissues occur at low variant allele fractions (VAFs), complicating detection. To benchmark strategies, the SMaHT Network created a cell-line mixture (1:49) and produced ultra-deep whole-genome sequencing using short and long reads (five centers, 180–500× each). We assembled a reference of 44,008 mosaic SNVs and 2,059 Indels, cross-validation between platforms to expose limits of short-read analysis. We also partitioned the genome by mappability to examine the impact of genomic context, added a negative reference set, and accounted for culture-derived mutations. When seven institutions applied eleven algorithms to mixture data, call sets were largely discordant across tools and replicates, partly reflecting stochastic presence of low-VAF mutations in biological replicants. For >2% VAF SNVs, sensitivity and precision approached ∼80% at ≥300×, with little gain from additional sequencing. This work provides a comprehensive framework for reliable detection of low-VAF mutations in non-cancer tissues and a valuable resource for the community.

29 September 2025 in bioRxiv
Verified
Preprint
Open access
BFBeverly J. Fu
Beverly J. Fu
VVVinayak V Viswanadham
Vinayak V Viswanadham
DMDominika Maziec
Dominika Maziec
HJHu Jin
Hu Jin
PPPeter Park
Peter Park
Background: The sequencing-by-synthesis technology by Illumina, Inc. enables efficient and scalable readouts of mutations from genomic data. To enhance sequencing speed and efficiency, Illumina has shifted from the four-color base calling chemistry of the HiSeq series to a two-color fluorescent dye chemistry in the NovaSeq series. Benchmarking sequencing artifacts due to biases in the newer chemistry is important to evaluate the quality of identified mutations. Results: We re-analyzed a series of whole-genome sequencing experiments in which the same samples were sequenced on the NovaSeq 6000 (two-color) and HiSeq X10 (four-color) platforms by independent groups. In several samples, we observed a higher frequency of T-to-G and A-to-C substitutions (“T>G”) at the read level for NovaSeq 6000 versus HiSeq X10. As the per-base error rate is still low, the artifactual substitutions have a negligible effect in identifying germline or high variant allele frequency (VAF) somatic mutations. However, such errors can confound the detection of low-VAF somatic variants in high-depth sequencing samples, particularly in studies of mosaic mutations in normal tissues, where variants have low read support and are called without a matched normal. The artifactual T>G variant calls disproportionately occur at NT[TG] trinucleotides, and we leveraged this observation to bioinformatically reduce the T>G excess in somatic mutation callsets. Conclusions: We identified a recurrent artifact specific to the Illumina two-color chemistry platform on the NovaSeq 6000 with the potential to contaminate low-VAF somatic mutation calls. Thus, an unexpected enrichment of T>G mutations in mosaicism studies warrants caution.